Mild clobetasol propionate cream regimen (10 to 30 g/day) showed no clear difference in adverse events at 1 year compared with standard clobetasol propionate cream regimen (40 g/day) (low certainty).
It is very uncertain whether any‐treatment‐dose vitamin D (greater than 400 IU/day) changes withdrawals due to adverse events compared with supplemental‐dose vitamin D (less than 400 IU/day) (very low certainty).
It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
Donepezil 23 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 10 mg/day (moderate certainty).
Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 5 mg/day (moderate certainty).
PPI triple therapy for 10 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
PPI triple therapy for 14 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 10 days (low certainty).
PPI triple therapy for 14 days probably leads to higher patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
The review found no eligible studies for this question.
Risedronate 5 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
It is very uncertain whether risedronate 5 mg/day changes serious adverse events compared with placebo (very low certainty).
Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with placebo (moderate certainty).
Febuxostat 40 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).
Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (moderate certainty).
Febuxostat 40 mg/day probably leads to higher serious Adverse Events compared with placebo (moderate certainty).
Febuxostat 120 mg/day showed no clear difference in serious Adverse events compared with placebo (moderate certainty).
Febuxostat 120 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).